There is no consensus in the existing literature regarding the effect of soluble fiber on the lipid profile of patients with type 2 diabetes mellitus (T2DM). This systematic review and meta-analysis of randomized controlled trials aimed to assess the effect of soluble fiber on triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in T2DM patients.
Methods
PubMed/MEDLINE, Scopus, and ISI Web of sciences were searched for RCTs up to 4 May 2024. Data from RCTs were pooled using the generic inverse variance method and expressed as weighted mean differences (WMD) with 95 % confidence interval (CIs).
Results
Pooled data from 38 RCTs reporting patient outcomes were evaluated for mean effects. Results indicated that soluble fiber significantly altered TG (WMD: −16.97 mg/dL, 95 % CI: −29.16 to −4.78, P = 0.021), HDL-C (WMD: 1.74 mg/dL, 95 % CI: 1.02–2.46, P < 0.001), LDL-C (WMD: −11.14 mg/dL, 95 % CI: −15.41 to −6.87, P < 0.001), and TC (WMD: −13.87 mg/dL, 95 % CI: −17.99 to −9.75, P = 0.027).
Conclusions
Soluble fiber supplementation has the potential to improve lipid profile in patients with T2DM, and may provide a feasible approach for improving metabolic health in T2DM patients.
背景：关于可溶性纤维对2型糖尿病（T2DM）患者血脂的影响，现有文献尚未达成共识。本研究对随机对照试验进行系统回顾和荟萃分析，旨在评估可溶性纤维对T2DM患者甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）和高密度脂蛋白胆固醇（HDL-C）的影响。方法：检索截至2024年5月4日的rct，检索PubMed/MEDLINE、Scopus和ISI Web of sciences。随机对照试验的数据采用通用反方差法合并，并以加权平均差（WMD）表示，置信区间为95% %。结果：对38项报告患者结局的随机对照试验的汇总数据进行平均效果评估。结果表明，可溶性纤维显著改变了TG （WMD: -16.97 mg/dL, 95 % CI: -29.16 ~ -4.78, P = 0.021）和HDL-C （WMD: 1.74 mg/dL, 95 % CI: 1.02 ~ 2.46, P ）。结论：补充可溶性纤维具有改善T2DM患者血脂的潜力，可能为改善T2DM患者代谢健康提供一种可行的途径。
{"title":"Effect of soluble fiber supplementation on lipid parameters in subjects with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials","authors":"Jitendra Gupta , Munthar Kadhim Abosaoda , Madhu Shukla , Suhas Ballal , Abhishek Kumar , Mamata Chahar , Suman Saini , Ish Kapila , Alireza Hadpoori","doi":"10.1016/j.prostaglandins.2024.106939","DOIUrl":"10.1016/j.prostaglandins.2024.106939","url":null,"abstract":"<div><h3>Background</h3><div>There is no consensus in the existing literature regarding the effect of soluble fiber on the lipid profile of patients with type 2 diabetes mellitus (T2DM). This systematic review and meta-analysis of randomized controlled trials aimed to assess the effect of soluble fiber on triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in T2DM patients.</div></div><div><h3>Methods</h3><div>PubMed/MEDLINE, Scopus, and ISI Web of sciences were searched for RCTs up to 4 May 2024. Data from RCTs were pooled using the generic inverse variance method and expressed as weighted mean differences (WMD) with 95 % confidence interval (CIs).</div></div><div><h3>Results</h3><div>Pooled data from 38 RCTs reporting patient outcomes were evaluated for mean effects. Results indicated that soluble fiber significantly altered TG (WMD: −16.97 mg/dL, 95 % CI: −29.16 to −4.78, P = 0.021), HDL-C (WMD: 1.74 mg/dL, 95 % CI: 1.02–2.46, P < 0.001), LDL-C (WMD: −11.14 mg/dL, 95 % CI: −15.41 to −6.87, P < 0.001), and TC (WMD: −13.87 mg/dL, 95 % CI: −17.99 to −9.75, P = 0.027).</div></div><div><h3>Conclusions</h3><div>Soluble fiber supplementation has the potential to improve lipid profile in patients with T2DM, and may provide a feasible approach for improving metabolic health in T2DM patients.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"176 ","pages":"Article 106939"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.prostaglandins.2024.106938
Kehao Yu , Wentao Song , Xinyu Tu , Ke Zhou , Kousalya Prabahar
Background and aim
Previous studies have reported on the relationship between vitamin D and the lipid profile in individuals with obesity or overweight, but results have been inconsistent. Hence, we conducted this meta-analysis and systematic review of randomized controlled trials to assess the effect of vitamin D on the lipid profile in individuals with overweight or obesity.
Methods
A meticulous search strategy was used in various databases, and article published up to November 2023 were included. The DerSimonian and Laird random effects model was applied to compute the weighted mean difference (WMD) and 95 % confidence intervals (CI) of the intervention on each variable.
Results
Vitamin D supplementation did not yield significant alterations in LDL-C (WMD: 2.10 mg/dL, CI: −5.20–9.41, p = 0.572), HDL-C (WMD: 1.49 mg/dL, 95 % CI: −1.55–4.55, P = 0.337), and TC concentrations (WMD: −1.99 mg/dL, CI: −8.21–4.22, P = 0.530). Conversely, a significant decrease in TG levels was observed studies conducted in individuals with comorbidities (WMD: −6.03 mg/dL, 95 % CI: −11.92 to −0.15, p = 0.044), vitamin D doses of ≥ 50000 IU/week (WMD: −20.87 mg/dL, 95 % CI: −39.63 to −2.11, P = 0.029), and subjects with baseline TG concentrations ≥ 150 mg/dl (WMD: −25.95 mg/dL, 95 % CI: −51.51 to −0.40, p = 0.046).
Conclusion
According to our study findings, vitamin D has significant effect on the hypertriglyceridemia in individuals with obesity or overweight. However, vitamin D has no significant effect on the LDL-C, HDL-C, and TC concentrations in individuals with obesity or overweight.
{"title":"The effect of vitamin D on the lipid profile in individuals with overweight or obesity: A meta-analysis and systematic review of randomized controlled trials","authors":"Kehao Yu , Wentao Song , Xinyu Tu , Ke Zhou , Kousalya Prabahar","doi":"10.1016/j.prostaglandins.2024.106938","DOIUrl":"10.1016/j.prostaglandins.2024.106938","url":null,"abstract":"<div><h3>Background and aim</h3><div>Previous studies have reported on the relationship between vitamin D and the lipid profile in individuals with obesity or overweight, but results have been inconsistent. Hence, we conducted this meta-analysis and systematic review of randomized controlled trials to assess the effect of vitamin D on the lipid profile in individuals with overweight or obesity.</div></div><div><h3>Methods</h3><div>A meticulous search strategy was used in various databases, and article published up to November 2023 were included. The DerSimonian and Laird random effects model was applied to compute the weighted mean difference (WMD) and 95 % confidence intervals (CI) of the intervention on each variable.</div></div><div><h3>Results</h3><div>Vitamin D supplementation did not yield significant alterations in LDL-C (WMD: 2.10 mg/dL, CI: −5.20–9.41, p = 0.572), HDL-C (WMD: 1.49 mg/dL, 95 % CI: −1.55–4.55, P = 0.337), and TC concentrations (WMD: −1.99 mg/dL, CI: −8.21–4.22, P = 0.530). Conversely, a significant decrease in TG levels was observed studies conducted in individuals with comorbidities (WMD: −6.03 mg/dL, 95 % CI: −11.92 to −0.15, p = 0.044), vitamin D doses of ≥ 50000 IU/week (WMD: −20.87 mg/dL, 95 % CI: −39.63 to −2.11, P = 0.029), and subjects with baseline TG concentrations ≥ 150 mg/dl (WMD: −25.95 mg/dL, 95 % CI: −51.51 to −0.40, p = 0.046).</div></div><div><h3>Conclusion</h3><div>According to our study findings, vitamin D has significant effect on the hypertriglyceridemia in individuals with obesity or overweight. However, vitamin D has no significant effect on the LDL-C, HDL-C, and TC concentrations in individuals with obesity or overweight.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"176 ","pages":"Article 106938"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142819028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-23DOI: 10.1016/j.prostaglandins.2024.106944
Katherine M Quinlivan, Isabella V Howard, Franciska Southan, Rachel L Bayer, Kimberly L Torres, Charles N Serhan, Dipak Panigrahy
Unresolved chronic inflammation, a hallmark of cancer, promotes tumor growth and metastasis in various cancer types. In contrast to blocking inflammation, stimulation of resolution of inflammation is an entirely novel approach to "resolve" inflammation. Resolution of inflammation mechanisms in cancer includes clearance of tumor debris, counter-regulation of pro-inflammatory eicosanoids and cytokines, and suppression of leukocyte infiltration. Conventional cytotoxic chemotherapy, radiation, anti-angiogenic therapy, and immune checkpoint inhibitors directly or indirectly can lead to the generation of pro-tumorigenic cellular debris. Over the past two decades, a potential paradigm shift has emerged in the inflammation field with the discovery of specialized pro-resolving mediators (SPMs), including resolvins, lipoxins, maresins, and protectins. SPMs are structurally distinct families of mediators grouped together by their pro-resolving "debris-clearing" functions. "Pro-resolving" therapies are in clinical development for various inflammation-driven diseases, including cancer. SPMs, as novel cancer therapeutics, have tremendous potential to enhance current cancer therapy. The mechanisms of SPMs as anti-cancer therapeutics are under active investigation by various laboratories worldwide. Here, we explore the current appreciation of the SPMs as innovative potential treatments designed to harness the unique anti-cancer activity of SPMs.
{"title":"Exploring the Unique Role of Specialized Pro-Resolving Mediators in Cancer Therapeutics.","authors":"Katherine M Quinlivan, Isabella V Howard, Franciska Southan, Rachel L Bayer, Kimberly L Torres, Charles N Serhan, Dipak Panigrahy","doi":"10.1016/j.prostaglandins.2024.106944","DOIUrl":"https://doi.org/10.1016/j.prostaglandins.2024.106944","url":null,"abstract":"<p><p>Unresolved chronic inflammation, a hallmark of cancer, promotes tumor growth and metastasis in various cancer types. In contrast to blocking inflammation, stimulation of resolution of inflammation is an entirely novel approach to \"resolve\" inflammation. Resolution of inflammation mechanisms in cancer includes clearance of tumor debris, counter-regulation of pro-inflammatory eicosanoids and cytokines, and suppression of leukocyte infiltration. Conventional cytotoxic chemotherapy, radiation, anti-angiogenic therapy, and immune checkpoint inhibitors directly or indirectly can lead to the generation of pro-tumorigenic cellular debris. Over the past two decades, a potential paradigm shift has emerged in the inflammation field with the discovery of specialized pro-resolving mediators (SPMs), including resolvins, lipoxins, maresins, and protectins. SPMs are structurally distinct families of mediators grouped together by their pro-resolving \"debris-clearing\" functions. \"Pro-resolving\" therapies are in clinical development for various inflammation-driven diseases, including cancer. SPMs, as novel cancer therapeutics, have tremendous potential to enhance current cancer therapy. The mechanisms of SPMs as anti-cancer therapeutics are under active investigation by various laboratories worldwide. Here, we explore the current appreciation of the SPMs as innovative potential treatments designed to harness the unique anti-cancer activity of SPMs.</p>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":" ","pages":"106944"},"PeriodicalIF":2.5,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142896954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-28DOI: 10.1016/j.prostaglandins.2024.106936
R Sundaram , K Muthu
Hyperlipidemia is a well-known risk factor for atherosclerosis and subsequent atherosclerotic cardiovascular diseases that are associated with high morbidity and mortality in obese and diabetic patients worldwide. The current study looked on rosmarinic acid's cadioprotective effects in rats fed a high-fat diet as there was no study on this aspect. The rats were given a high-fat diet comprising of 84.3 % conventional laboratory rat chow, 5 % lard, 10 % egg yolk powder, 0.2 % cholesterol, and 0.5 % bile salt to produce hypercholesterolemia. Over a span of eight weeks. The plasma lipid profile, cardiac marker enzymes, membrane bound ATPases, lysosomal enzymes, CRP, fibrinogen, proinflammatory cytokines (IL-1β, IL-6,TNF-α, NF-κB),anti-inflammatory cytokine(IL-10) lipid peroxidation markers, enzymatic and non-enzymatic antioxidant enzymes activity were examined. The thoracic aorta's histopathology was also analyzed. It was discovered that the rats fed a high-fat diet had hypercholesterolemia and showed aberrant values in the aforementioned parameters. However, rats given rosmarinic acid (100 mg/kg b.w.) had these anomalies reversed to near-normal levels. The biochemical investigation was corroborated by enhanced histological examination of the thoracic aorta in rats suffering from hypercholestolemia. The effects of rosmarinic acid on a number of measures were similar to those of the prescription medication simvastatin. These findings revealed that rosmarinic acid is an important component in the cardiovascular system's defence against a high-fat diet induced hypercholesterolemia
{"title":"Rosmarinic acid alleviates the cardiac abnormalities in high fat diet induced hypercholesterolemic rats","authors":"R Sundaram , K Muthu","doi":"10.1016/j.prostaglandins.2024.106936","DOIUrl":"10.1016/j.prostaglandins.2024.106936","url":null,"abstract":"<div><div>Hyperlipidemia is a well-known risk factor for atherosclerosis and subsequent atherosclerotic cardiovascular diseases that are associated with high morbidity and mortality in obese and diabetic patients worldwide. The current study looked on rosmarinic acid's cadioprotective effects in rats fed a high-fat diet as there was no study on this aspect. The rats were given a high-fat diet comprising of 84.3 % conventional laboratory rat chow, 5 % lard, 10 % egg yolk powder, 0.2 % cholesterol, and 0.5 % bile salt to produce hypercholesterolemia. Over a span of eight weeks. The plasma lipid profile, cardiac marker enzymes, membrane bound ATPases, lysosomal enzymes, CRP, fibrinogen, proinflammatory cytokines (IL-1β, IL-6,TNF-α, NF-κB),anti-inflammatory cytokine(IL-10) lipid peroxidation markers, enzymatic and non-enzymatic antioxidant enzymes activity were examined. The thoracic aorta's histopathology was also analyzed. It was discovered that the rats fed a high-fat diet had hypercholesterolemia and showed aberrant values in the aforementioned parameters. However, rats given rosmarinic acid (100 mg/kg b.w.) had these anomalies reversed to near-normal levels. The biochemical investigation was corroborated by enhanced histological examination of the thoracic aorta in rats suffering from hypercholestolemia. The effects of rosmarinic acid on a number of measures were similar to those of the prescription medication simvastatin. These findings revealed that rosmarinic acid is an important component in the cardiovascular system's defence against a high-fat diet induced hypercholesterolemia</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"176 ","pages":"Article 106936"},"PeriodicalIF":2.5,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-09DOI: 10.1016/j.prostaglandins.2024.106934
Zhu Haijun , Zhang Ke , Zhang Dawei , Amir Reza Haedi , Elika Poorasadollah , Cheng Cheng
Considering dyslipidemia's impact on cardiovascular disease and even chronic illnesses and the beneficial effect of glucomannan on dyslipidemia, this study aimed to examine how glucomannan affects lipid profile parameters thoroughly. Using standard keywords, the databases Scopus, PubMed, Embase, Web of Science databases, and Google Scholar were searched from inception to December 2024. Based on our finding, glucomannan significantly reduced total cholesterol (TC) (SMD: −2.26; 95 % CI: −2.98, −1.55, p <0.001), low-density lipoprotein cholesterol (LDL-C) levels (SMD: −2.57; 95 % CI: −3.41, −1.74; p<0.001), but not effect on high-density lipoprotein cholesterol (HDL-C) (SMD: −0.33; 95 % CI: −0.70, 0.03, p=0.075), and triglyceride (TG) (SMD: −0.16; 95 % CI: −0.59, 0.27, p =0.473). However, these significant decreases are not clinically important. Therefore, glucomannan only can be considered as an adjunctive therapeutic approach in managing dyslipidemia.
考虑到血脂异常对心血管疾病甚至慢性疾病的影响，以及葡甘聚糖对血脂异常的有益作用，本研究旨在深入研究葡甘聚糖如何影响血脂谱参数。本研究使用标准关键词，在 Scopus、PubMed、Embase、Web of Science 数据库和 Google Scholar 等数据库中检索了从开始到 2024 年 12 月的所有研究。研究发现，葡甘聚糖能显著降低总胆固醇（TC）（SMD：-2.26；95% CI：-2.98，-1.55，p
{"title":"Does glucomannan supplementation exert profitable effects on serum lipid profile in adults? A systematic review and meta-analysis","authors":"Zhu Haijun , Zhang Ke , Zhang Dawei , Amir Reza Haedi , Elika Poorasadollah , Cheng Cheng","doi":"10.1016/j.prostaglandins.2024.106934","DOIUrl":"10.1016/j.prostaglandins.2024.106934","url":null,"abstract":"<div><div>Considering dyslipidemia's impact on cardiovascular disease and even chronic illnesses and the beneficial effect of glucomannan on dyslipidemia, this study aimed to examine how glucomannan affects lipid profile parameters thoroughly. Using standard keywords, the databases Scopus, PubMed, Embase, Web of Science databases, and Google Scholar were searched from inception to December 2024. Based on our finding, glucomannan significantly reduced total cholesterol (TC) (SMD: −2.26; 95 % CI: −2.98, −1.55, p <0.001), low-density lipoprotein cholesterol (LDL-C) levels (SMD: −2.57; 95 % CI: −3.41, −1.74; p<0.001), but not effect on high-density lipoprotein cholesterol (HDL-C) (SMD: −0.33; 95 % CI: −0.70, 0.03, p=0.075), and triglyceride (TG) (SMD: −0.16; 95 % CI: −0.59, 0.27, p =0.473). However, these significant decreases are not clinically important. Therefore, glucomannan only can be considered as an adjunctive therapeutic approach in managing dyslipidemia.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"176 ","pages":"Article 106934"},"PeriodicalIF":2.5,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142627150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-08DOI: 10.1016/j.prostaglandins.2024.106920
Juanjuan Zhu , Bingbing Wang , Sanaz Asemani , Shiwei Bao , Niannian Tian
Objective
The research aimed to investigate the Association between Vitamin D deficiency and childhood obesity and its Impact on children’s serum calcium, alkaline Phosphatase, and bone Age.
Methods
The study analyzed clinical data from 159 school-aged children who underwent medical examinations. The children were divided into a 25-(OH)D3 deficiency group and a non-25-(OH)D3 deficiency group based on their serum 25-hydroxy Vitamin D3 levels. The two groups were compared regarding BMI, TC, TG, FBG, HbA1c, Ca, ALP, and bone age differences.
Results
Individuals with a deficiency in 25-(OH)D3 exhibited higher levels of BMI, TC, TG, and ALP, and lower levels of Ca and bone age than those without the deficiency. These differences were statistically significant (P<0.05). Further analysis revealed a negative association between 25-(OH)D3 levelsa positive correlation between Ca and bone age, and a positive correlation with, BMI, TC, TG, and ALP.
Conclusion
The deficiency of 25-(OH)D3 in school-aged children is linked to obesity and impacts bone growth. Monitoring vitamin D levels is crucial for clinical practitioners.
研究目的研究旨在探讨维生素 D 缺乏与儿童肥胖之间的关联及其对儿童血清钙、碱性磷酸酶和骨龄的影响 方法：研究分析了 159 名接受体检的学龄儿童的临床数据。根据儿童血清中 25- 羟基维生素 D3 的水平，将其分为 25-(OH)D3 缺乏组和非 25-(OH)D3 缺乏组。两组儿童的体重指数（BMI）、总胆固醇（TC）、总胆固醇（TG）、血糖（FBG）、糖化血红蛋白（HbA1c）、钙（Ca）、谷丙转氨酶（ALP）和骨龄差异进行了比较：结果：与缺乏 25-(OH)D3 的人相比，缺乏 25-(OH)D3 的人的 BMI、TC、TG 和 ALP 水平较高，而 Ca 和骨龄水平较低。这些差异具有统计学意义（PC结论：学龄儿童缺乏 25-(OH)D3 与肥胖有关，并影响骨骼生长。监测维生素 D 水平对临床医师至关重要。
{"title":"The association between vitamin D deficiency and childhood obesity and its impact on children’s serum calcium, alkaline phosphatase, and bone age","authors":"Juanjuan Zhu , Bingbing Wang , Sanaz Asemani , Shiwei Bao , Niannian Tian","doi":"10.1016/j.prostaglandins.2024.106920","DOIUrl":"10.1016/j.prostaglandins.2024.106920","url":null,"abstract":"<div><h3>Objective</h3><div>The research aimed to investigate the Association between Vitamin D deficiency and childhood obesity and its Impact on children’s serum calcium, alkaline Phosphatase, and bone Age.</div></div><div><h3>Methods</h3><div>The study analyzed clinical data from 159 school-aged children who underwent medical examinations. The children were divided into a 25-(OH)D3 deficiency group and a non-25-(OH)D3 deficiency group based on their serum 25-hydroxy Vitamin D3 levels. The two groups were compared regarding BMI, TC, TG, FBG, HbA1c, Ca, ALP, and bone age differences.</div></div><div><h3>Results</h3><div>Individuals with a deficiency in 25-(OH)D3 exhibited higher levels of BMI, TC, TG, and ALP, and lower levels of Ca and bone age than those without the deficiency. These differences were statistically significant (P<0.05). Further analysis revealed a negative association between 25-(OH)D3 levelsa positive correlation between Ca and bone age, and a positive correlation with, BMI, TC, TG, and ALP.</div></div><div><h3>Conclusion</h3><div>The deficiency of 25-(OH)D3 in school-aged children is linked to obesity and impacts bone growth. Monitoring vitamin D levels is crucial for clinical practitioners.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"176 ","pages":"Article 106920"},"PeriodicalIF":2.5,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142627148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-28DOI: 10.1016/j.prostaglandins.2024.106915
LUO Zhong-yong , Deng ZHi-qing , Xia Li-qiong , Elika Poorasadollah , Shabnam Shirvani
Recent interventional investigations suggest the beneficial impact of propolis supplementation on inflammatory biomarkers; however, the results have not been summarized in a comprehensive meta-analysis. We conducted this meta-analysis to summarize all available data and provide clear evidence for whether propolis supplementation affects inflammatory biomarkers. This systematic review with meta-analysis was performed by searching databases (PubMed/Medline, Web of Science, Scopus, and Embase) until February 2024. It included randomized clinical trials (RCTs) assessing the effects of propolis supplementation on inflammatory biomarkers in adults. This review included 20 RCTs with a total of 1139 participants. The propolis supplementation significantly reduced IL-6 (WMD = −2.48; 95 % CI: −4.62, −0.34; P = 0.023) and TNF-α (WMD = −0.86; 95 % CI: −1.45, −0.26; P = 0.005) compared with control groups. Although the CRP concentration was not reduced (WMD = 0.01; 95 % CI: −0.03, 0.05, P = 0.646), a significant reduction in CRP levels was revealed in supplementation durations ≥ 10 weeks. These results suggest that propolis has a beneficial effect on TNF-α and IL-6 levels and may be an effective adjunctive therapy for diseases where inflammation is a key factor in the etiology. Due to the limited number of studies, clinical diversity, and other limitations, it is necessary to conduct more high-quality studies to provide more precise and comprehensive recommendations.
{"title":"The impact of propolis supplementation on inflammatory biomarkers: A meta-analysis and systematic review of randomized controlled clinical trials","authors":"LUO Zhong-yong , Deng ZHi-qing , Xia Li-qiong , Elika Poorasadollah , Shabnam Shirvani","doi":"10.1016/j.prostaglandins.2024.106915","DOIUrl":"10.1016/j.prostaglandins.2024.106915","url":null,"abstract":"<div><div>Recent interventional investigations suggest the beneficial impact of propolis supplementation on inflammatory biomarkers; however, the results have not been summarized in a comprehensive meta-analysis. We conducted this meta-analysis to summarize all available data and provide clear evidence for whether propolis supplementation affects inflammatory biomarkers. This systematic review with meta-analysis was performed by searching databases (PubMed/Medline, Web of Science, Scopus, and Embase) until February 2024. It included randomized clinical trials (RCTs) assessing the effects of propolis supplementation on inflammatory biomarkers in adults. This review included 20 RCTs with a total of 1139 participants. The propolis supplementation significantly reduced IL-6 (WMD = −2.48; 95 % CI: −4.62, −0.34; P = 0.023) and TNF-α (WMD = −0.86; 95 % CI: −1.45, −0.26; P = 0.005) compared with control groups. Although the CRP concentration was not reduced (WMD = 0.01; 95 % CI: −0.03, 0.05, P = 0.646), a significant reduction in CRP levels was revealed in supplementation durations ≥ 10 weeks. These results suggest that propolis has a beneficial effect on TNF-α and IL-6 levels and may be an effective adjunctive therapy for diseases where inflammation is a key factor in the etiology. Due to the limited number of studies, clinical diversity, and other limitations, it is necessary to conduct more high-quality studies to provide more precise and comprehensive recommendations.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"175 ","pages":"Article 106915"},"PeriodicalIF":2.5,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142561251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Diet represents an important set of potential risk factors for rheumatoid arthritis (RA), a known inflammatory condition. This case-control study examined the association between the inflammatory potential of diet, as determined by the dietary inflammatory index (DII®), and RA risk in an Iranian population. The present Case–control study was conducted on 100 RA patients and 200 age- and sex-matched controls in Isfahan, Iran. The presence of RA was determined by expert Rheumatologist assessment based on the American College of Rheumatology definitions. A 168-item food frequency questionnaire was used to collect dietary intake from which DII scores were computed. Odds ratios (OR) and 95 % confidence intervals (CI) for the association between the DII, expressed in tertiles, and RA risk were estimated by two multivariable logistic regression models, one crude model and one in which we controlled for important potential confounders. In the crude model, individuals in the top DII tertile (most pro-inflammatory diet) had more than triple the risk of RA compared to those in the lowest tertile (ORtertile3vs1= 3.57; 95 % CI, 1.95–6.53; p< 0.001). The association was essentially unchanged after controlling for potential confounders (OR tertile3vs1 = 3.83; 95 % CI, 1.66–8.81; p<0.001). We found that a pro-inflammatory diet is associated with increased risk of RA. Higher volume studies are needed to confirm the results.
{"title":"The association between dietary inflammatory index with risk rheumatoid arthritis: A case-control study","authors":"Zhejianyi Gao , Farhad Alishahi , Amirabbas Faridpour , Saeed Nezamoleslami , Shokufeh Nezamoleslami , Reza Ghiasvand , Ariyo Movahedi , Nitin Shivappa , James R. Hébert , Mahsa Jalalinejad , Asal Ataie-Jafari","doi":"10.1016/j.prostaglandins.2024.106916","DOIUrl":"10.1016/j.prostaglandins.2024.106916","url":null,"abstract":"<div><div>Diet represents an important set of potential risk factors for rheumatoid arthritis (RA), a known inflammatory condition. This case-control study examined the association between the inflammatory potential of diet, as determined by the dietary inflammatory index (DII®), and RA risk in an Iranian population. The present Case–control study was conducted on 100 RA patients and 200 age- and sex-matched controls in Isfahan, Iran. The presence of RA was determined by expert Rheumatologist assessment based on the American College of Rheumatology definitions. A 168-item food frequency questionnaire was used to collect dietary intake from which DII scores were computed. Odds ratios (OR) and 95 % confidence intervals (CI) for the association between the DII, expressed in tertiles, and RA risk were estimated by two multivariable logistic regression models, one crude model and one in which we controlled for important potential confounders. In the crude model, individuals in the top DII tertile (most pro-inflammatory diet) had more than triple the risk of RA compared to those in the lowest tertile (OR<sub>tertile3vs1</sub>= 3.57; 95 % CI, 1.95–6.53; p<strong><</strong> 0.001<strong>)</strong>. The association was essentially unchanged after controlling for potential confounders (OR <sub>tertile3vs1</sub> = 3.83; 95 % CI, 1.66–8.81; p<strong><</strong>0.001<strong>)</strong>. We found that a pro<strong>-</strong>inflammatory diet is associated with increased risk of RA. Higher volume studies are needed to confirm the results.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"175 ","pages":"Article 106916"},"PeriodicalIF":2.5,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Non-septic shock is a serious condition leading to multiple organ dysfunction. Although targeting the mammalian target of the rapamycin complex 1 (mTORC1) signaling pathway exerts potent anti-inflammatory activity, little is known about mTORC2’s contribution to non-septic shock. Thus, our research aims to investigate mTORC2's contribution and associated changes of IκB kinase (IKKα)/inhibitor κB (IκB-α)/nuclear factor-ĸB (NF-κB) pathway on Zymosan (ZYM)-induced non-septic rat model using the novel mTORC2 selective inhibitor JR-AB2–011. Rats were given saline (4 ml/kg), dimethylsulfoxide (DMSO) (4 ml/kg), ZYM (500 mg/kg), and (or) JR-AB2–011 (1 mg/kg). Mean arterial pressure (MAP) and heart rate (HR) of rats were recorded. JR-AB2–011 reversed both ZYM-induced reduction in MAP and increase in HR. Protein expression and/or phosphorylation of rictor, protein kinase B (Akt), IκB-α, IKKα, NF-κB p65, inducible nitric oxide synthase (iNOS), nitrotyrosine, cyclooxygenase 2 (COX-2), tumor necrosis factor (TNF)-α, interleukin (IL)-1β, besides prostaglandin (PG) E2 levels were measured. The enhanced expression of the proteins mentioned above has been inhibited by JR-AB2–011. These data suggest mTORC2’s promising role in ZYM-induced hypotension and systemic inflammation mediated via IKKα/IκB-α/NF-κB pathway.
{"title":"Protection by selective mTORC2 inhibition of Zymosan-induced hypotension and systemic inflammation mediated via IKKα/IκB-α/NF-κB activation","authors":"Zainab Sabrie , Meryem Temiz-Resitoglu , Taskin Kalkan , Banu Kilic , Bahar Tunctan , Kafait U. Malik , Seyhan Sahan-Firat","doi":"10.1016/j.prostaglandins.2024.106918","DOIUrl":"10.1016/j.prostaglandins.2024.106918","url":null,"abstract":"<div><div>Non-septic shock is a serious condition leading to multiple organ dysfunction. Although targeting the mammalian target of the rapamycin complex 1 (mTORC1) signaling pathway exerts potent anti-inflammatory activity, little is known about mTORC2’s contribution to non-septic shock. Thus, our research aims to investigate mTORC2's contribution and associated changes of IκB kinase (IKKα)/inhibitor κB (IκB-α)/nuclear factor-ĸB (NF-κB) pathway on Zymosan (ZYM)-induced non-septic rat model using the novel mTORC2 selective inhibitor JR-AB2–011. Rats were given saline (4 ml/kg), dimethylsulfoxide (DMSO) (4 ml/kg), ZYM (500 mg/kg), and (or) JR-AB2–011 (1 mg/kg). Mean arterial pressure (MAP) and heart rate (HR) of rats were recorded. JR-AB2–011 reversed both ZYM-induced reduction in MAP and increase in HR. Protein expression and/or phosphorylation of rictor, protein kinase B (Akt), IκB-α, IKKα, NF-κB p65, inducible nitric oxide synthase (iNOS), nitrotyrosine, cyclooxygenase 2 (COX-2), tumor necrosis factor (TNF)-α, interleukin (IL)-1β, besides prostaglandin (PG) E<sub>2</sub> levels were measured. The enhanced expression of the proteins mentioned above has been inhibited by JR-AB2–011. These data suggest mTORC2’s promising role in ZYM-induced hypotension and systemic inflammation mediated via IKKα/IκB-α/NF-κB pathway.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"175 ","pages":"Article 106918"},"PeriodicalIF":2.5,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Although numerous trials have demonstrated the benefits of purslane on patients with type 2 diabetes mellitus (T2DM), the results of some studies reject such effect. We elucidated the influence of purslane on c-reactive protein (CRP), lipid profile, and glycemic control in patients with T2DM. We conducted a systematic search on Web of Sciences, Scopus, the Cochrane Library, PubMed, and Embase, to identify studies published from their inception to February 10, 2024. The random effect model was used to calculate the combined effect, the weighted mean differences (WMDs) and its 95 % confidence interval (CI). Purslane supplementation significantly reduced fasting blood glucose (FBG) levels (WMD: −15.01; 95 % CI: −25.31, −4.71, p= 0.004), total cholesterol (TC) (WMD: −17.75; 95 % CI: −26.06, −9.45; p< 0.001), triglyceride (TG) (WMD: −21.30; 95 % CI: −32.59, −10.00; p< 0.001), low-density lipoprotein cholesterol (LDL-C) (WMD: −6.10; 95 % CI: −9.52, −2.68; p< 0.001), and CRP levels (WMD: −1.44; 95 % CI: −2.25, −0.63; p< 0.001), and increased high-density lipoprotein cholesterol (HDL-C) (WMD: 6.17; 95 % CI: 2.53, 9.80; p< 0.001). Also, purslane did not significant effect on serum levels of insulin, hemoglobin A1C (HbA1c), and homeostatic model Assessment for insulin resistance (HOMA-IR). The results of our study showed that purslane supplementation improved FBG, and lipid profile levels, but did not affect HOMA-IR, insulin, and HbA1c levels. However, high-quality trials are needed to approve our results.
{"title":"The effects of purslane (Portulaca oleracea) on C-reactive protein, lipid profile, and glycemic control in patients with type 2 diabetes mellitus: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials","authors":"Guo Donglin , Roya Birjandi , Fatemeh Moghimi Esfandabadi , Amirreza Haedi , Chen Fujiang","doi":"10.1016/j.prostaglandins.2024.106917","DOIUrl":"10.1016/j.prostaglandins.2024.106917","url":null,"abstract":"<div><div>Although numerous trials have demonstrated the benefits of purslane on patients with type 2 diabetes mellitus (T2DM), the results of some studies reject such effect. We elucidated the influence of purslane on c-reactive protein (CRP), lipid profile, and glycemic control in patients with T2DM. We conducted a systematic search on Web of Sciences, Scopus, the Cochrane Library, PubMed, and Embase, to identify studies published from their inception to February 10, 2024. The random effect model was used to calculate the combined effect, the weighted mean differences (WMDs) and its 95 % confidence interval (CI). Purslane supplementation significantly reduced fasting blood glucose (FBG) levels (WMD: −15.01; 95 % CI: −25.31, −4.71, p= 0.004), total cholesterol (TC) (WMD: −17.75; 95 % CI: −26.06, −9.45; p< 0.001), triglyceride (TG) (WMD: −21.30; 95 % CI: −32.59, −10.00; p< 0.001), low-density lipoprotein cholesterol (LDL-C) (WMD: −6.10; 95 % CI: −9.52, −2.68; p< 0.001), and CRP levels (WMD: −1.44; 95 % CI: −2.25, −0.63; p< 0.001), and increased high-density lipoprotein cholesterol (HDL-C) (WMD: 6.17; 95 % CI: 2.53, 9.80; p< 0.001). Also, purslane did not significant effect on serum levels of insulin, hemoglobin A1C (HbA1c), and homeostatic model Assessment for insulin resistance (HOMA-IR). The results of our study showed that purslane supplementation improved FBG, and lipid profile levels, but did not affect HOMA-IR, insulin, and HbA1c levels. However, high-quality trials are needed to approve our results.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"175 ","pages":"Article 106917"},"PeriodicalIF":2.5,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号